Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: An update

Drug News and Perspectives

Volumn 20, Issue 3, 2007, Pages 171-181

  Horváth, Eszter M ^b   Szabó, Csaba ^a  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE;

CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GLIOMA; HEART FAILURE; HEART INFARCTION; HEMODYNAMIC STRESS; HUMAN; MELANOMA; NICK END LABELING; NONHUMAN; PATHOPHYSIOLOGY; POLYMERIZATION; REVIEW; SIDE EFFECT; STROKE; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 34250370941     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.3.1092098     Document Type: Review

References (99)

1. de Murcia, G., Schreiber, V., Molinete, M. et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 1994, 138: 15-24.
2. Le Rhun, Y., Kirkland, J.B. and Shah, G.M. Cellular responses to DNA damage in the absence of poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 1998, 245: 1-10.
3. Szabo, C. Cell death: The role of PARP. CRC Press, Boca Raton, 2000.
4. de Murcia, G. and Shall, S. (Eds.). From DNA Damage and Stress Signaling to Cell Death; Poly ADP-Ribosylation Reactions. Oxford University Press, Oxford 2000.
5. Virag, L. and Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54: 375-429.
6. Jagtap, P. and Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drag Discov 2005, 4: 421-40.
7. Sims, J.L., Berger, S.J. and Berger, N.A. Poly(ADP-ribose) polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5′-triphosphate pools in DNA-damaged cells: Mechanism of stimulation of unscheduled DNA synthesis. Biochemistry 1983, 22: 5188-94.
8. Szabo, C., Zingarelli, B., O'Connor, M. and Salzman, A.L. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 1996, 93: 1753-8.
9. Szabo, G., Liaudet, L., Hagl, S. and Szabo, C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 2004, 61: 471-80.
10. Gilad, E., Zingarelli, B., Salzman, A.L. and Szabo, C. Protection by inhibition of poly(ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 1997, 29: 2585-97.
11. Bowes, J., Ruetten, H., Martorana, P.A., Stockhausen, H. and Thiemermann, C. Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig. Eur J Pharmacol 1998, 359: 143-50.
12. Bowes, J., Piper, J. and Thiemermann, C. Inhibitors of the activity of poly (ADP-ribose) synthetase reduce the cell death caused by hydrogen peroxide in human cardiac myoblasts. Br J Pharmacol 1998, 124: 1760-6.
13. Bowes, J., McDonald, M.C., Piper, J. and Thiemermann, C. Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Cardiovasc Res 1999, 41: 126-34.
14. Pillai, J.B., Isbatan, A., Imai, S. and Gupta, M.P. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005, 280: 43121-30.
15. Pieper, A.A., Walles, T., Wei, G. et al. Myocardial postischemic injury is reduced by polyADPribose polymerase-1 gene disruption. Mol Med 2000, 6: 271-82.
16. Grupp, I.L., Jackson, T.M., Hake, P., Grupp, G. and Szabo, C. Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts. J Mol Cell Cardiol 1999, 31: 297-303.
17. Zhou, H.Z., Swanson, R.A., Simonis, U., Ma, X., Cecchini, G. and Gray, M.O. Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am J Physiol Heart Circ Physiol 2006, 291: H714-23.
18. Szabados, E., Literati-Nagy, P., Farkas, B. and Sumegi, B. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol 2000, 59: 937-45.
19. Docherty, J.C., Kuzio, B., Silvester, J.A., Bowes, J. and Thiemermann, C. An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br J Pharmacol 1999, 127: 1518-24.
20. Szabados, E., Fischer, G.M., Gallyas, F. Jr., Kispal, G. and Sumegi, B. Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart. Free Radic Biol Med 1999, 27: 1103-13.
21. Thiemermann, C., Bowes, J., Myint, F.P. and Vane, J.R. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A 1997, 94: 679-83.
22. Yamazaki, K., Miwa, S., Ueda, K. et al. Prevention of myocardial reperfusion injury by poly(ADP-ribose) synthetase inhibitor, 3-aminobenzamide, in cardioplegic solution: In vitro study of isolated rat heart model. Eur J Cardiothorac Surg 2004, 26: 270-5.
23. Zingarelli, B., Salzman, A.L. and Szabo, C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998, 83: 85-94.
24. Yang, Z., Zingarelli, B. and Szabo, C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 2000, 13: 60-6.
25. Xiao, C.Y., Chen, M., Zsengeller, Z. et al. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 2005, 312: 891-8.
26. Liaudet, L., Szabo, E., Timashpolsky, L., Virag, L., Cziraki, A. and Szabo, C. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: Long-term morphological and functional consequences. Br J Pharmacol 2001, 133: 1424-30.
27. Zingarelli, B., Cuzzocrea, S., Zsengeller, Z., Salzman, A.L. and Szabo, C. Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 1997, 36: 205-15.
28. Xiao, C.Y., Chen, M., Zsengeller, Z. and Szabo, C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 2004, 310: 498-504.
29. Faro, R., Toyoda, Y., McCully, J.D. et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg 2002, 73: 575-81.
30. Liaudet, L., Yang, Z., Al-Affar, E.B. and Szabo, C. Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. Mol Med 2001, 7: 406-17.
31. Szabo, G., Soos, P., Bahrle, S. et al. Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg 2004, 25: 825-32.
32. Szabo, G., Soos, P., Mandera, S. et al. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 2004, 21: 426-32.
33. Szabo, G., Buhmann, V., Andrasi, T. et al. Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest. J Thorac Cardiovasc Surg 2003, 126: 651-8.
34. Andrasi, T.B., Blazovics, A., Szabo, G., Vahl, C.F. and Hagl, S. Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. Am J Physiol Heart Circ Physiol 2005, 288: H2972-8.
35. Szabo, G., Bahrle, S., Stumpf, N. et al. Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002, 90: 100-6.
36. Pacher, P., Liaudet, L., Mabley, J., Komjati, K. and Szabo, C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 2002, 40: 1006-16.
37. Pacher, P., Liaudet, L., Mabley, J.G., Cziraki, A., Hasko, G. and Szabo, C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006, 17: 369-75.
38. Palfi, A., Toth, A., Hanto, K. et al. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. J Mol Cell Cardiol 2006, 41: 149-59.
39. Murthy, K.G., Xiao, C.Y., Mabley, J.G., Chen, M. and Szabo, C. Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction. Shock 2004, 21: 230-4.
40. Pillai, J.B., Russell, H.M., Raman, J., Jeevanandam, V. and Gupta, M.P. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005, 288: H486-96.
41. Molnar, A., Toth, A., Bagi, Z. et al. Activation of the PARP pathway in human heart failure. Mol Med 2006, 12: 143-52.
42. Soriano, F.G., Nogueira, A.C., Caldini, E.G. et al. Potential role of poly(adenosine 5′-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 2006, 34: 1073-9.
43. Toth-Zsamboki, E., Horvath, E.M., Vargova, K. et al. Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med 2006, 12: 221-8.
44. Ramlawi, B., Feng, J., Mieno, S. et al. Indices of apoptosis activation after blood cardioplegia and cardiopulmonary bypass. Circulation 2006, 114(1 Suppl): 1257-63.
45. Toth, O., Szabo, C., Kecskes, M., Poto, L., Nagy, A. and Losonczy, H. In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci 2006, 79: 317-23.
46. Hagberg, H., Wilson, M.A., Matsushita, H. et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 2004, 90: 1068-75.
47. McCullough, L.D., Zeng, Z., Blizzard, K.K., Debchoudhury, I. and Hum, P.D. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: Male toxicity, female protection. J Cereb Blood Flow Metab 2005, 25: 502-12.
48. Mabley, J.G., Horvath, E.M., Murthy, K.G. et al. Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther 2005, 315: 812-20.
49. Graziani, G. and Szabo, C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005, 52: 109-18.
50. Woon, E.C. and Threadgill, M.D. Poly(ADP-ribose)polymerase inhibition - where now? Curr Med Chem 2005, 12: 2373-92.
51. Haince, J.F., Rouleau, M., Hendzel, M.J., Masson, J.Y. and Poirier, G.G. Targeting poly(ADP-ribosyl)ation: A promising approach in cancer therapy. Trends Mol Med 2005, 11: 456-63.
52. Tentori, L. and Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005, 52: 25-33.
53. Curtin, N.J. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005, 7: 1-20.
54. Tentori, L., Leonetti, C., Scarsella, M. et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002, 99: 2241-4.
55. Tentori, L., Leonetti, C., Scarsella, M. et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 2005, 26: 415-22.
56. Tentori, L., Leonetti, C., Scarsella, M. et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003, 9: 5370-9.
57. Tentori, L., Portarena, I., Torino, F., Scerrati, M., Navarra, P. and Graziani, G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002, 40: 44-54.
58. Miknyoczki, S.J., Jones-Bolin, S., Pritchard, S. et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003, 2: 371-82.
59. Tentori, L., Portarena, I., Barbarino, M. et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly(ADP-ribose) polymerase inhibitor. Mol Pharmacol 2003, 63: 192-202.
60. Tentori, L., Leonetti, C., Scarsella, M. et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 2005, 41: 2948-57.
61. Cheng, C.L., Johnson, S.P., Keir, S.T. et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005, 4: 1364-8.
62. White, A.W., Curtin, N.J., Eastman, B.W. et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 2004, 14: 2433-7.
63. White, A.W., Almassy, R., Calvert, A.H. et al. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem 2000, 43: 4084-97.
64. Calabrese, C.R., Almassy, R., Barton, S. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AGI4361. J Natl Cancer Inst 2004, 96: 56-67.
65. Delaney, C.A., Wang, L.Z., Kyle, S. et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000, 6: 2860-7.
66. Liu, L., Taverna, P., Whitacre, C.M., Chatterjee, S. and Gerson, S.L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999, 5: 2908-17.
67. Wedge, S.R., Porteous, J.K. and Newlands, E.S. 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996, 74: 1030-6.
68. Calabrese, C.R., Batey, M.A., Thomas, H.D. et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clin Cancer Res 2003, 9: 2711-8.
69. Skalitzky, D.J., Marakovits, J.T., Maegley, K.A. et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 2003, 46: 210-3.
70. Curtin, N.J., Wang, L.Z., Yiakouvaki, A. et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AGI4361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004, 10: 881-9.
71. Curtin, N.J. PARP-1: A new target for cancer treatment. Cancer Research UK Scientific YearBook 2003, (2002-2003): 52-4.
72. Tentori, L., Leonetti, C., Scarsella, M. et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006, 20: 1709-11.
73. Canan Koch, S.S., Thoresen, L.H., Tikhe, J.G. et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anti-cancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. J Med Chem 2002, 45: 4961-74.
74. Tentori, L., Orlando, L., Lacal, P.M. et al. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997, 52: 249-58.
75. Tentori, L., Portarena, I., Vernole, P. et al. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol 2001, 47: 361-9.
76. Plummer, E.R., Middleton, M.R., Jones, C. et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005, 11: 3402-9.
77. Bryant, H.E., Schultz, N., Thomas, H.D. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434: 913-7.
78. Farmer, H., McCabe, N., Lord, C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434: 917-21.
79. McCabe, N., Turner, N.C., Lord, C.J. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66: 8109-15.
80. De Soto, J.A., Wang, X., Tominaga, Y. et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006, 2: 179-85.
81. De Soto, J.A. and Deng, C.X. PARP-1 inhibitors: Are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 2006, 3: 117-23.
82. Yung, T.M., Sato, S. and Satoh, M.S. Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction. J Biol Chem 2004, 279: 39686-96.
83. Malanga, M. and Althaus, F.R. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 2004, 279: 5244-8.
84. Nguewa, P.A., Fuertes, M.A., Cepeda, V. et al. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006, 2: 47-53.
85. Boulton, S., Kyle, S. and Durkacz, B.W. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999, 20: 199-203.
86. Brock, W.A., Milas, L., Bergh, S., Lo, R., Szabo, C. and Mason, K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004, 205: 155-60.
87. Martin-Oliva, D., Aguilar-Quesada, R., O'Valle, F. et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 2006, 66: 5744-56.
88. Tentori, L., Portarena, I., Bonmassar, E. and Graziani, G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ 2001, 8: 457-69.
89. Obrosova, I.G., Minchenko, A.G., Frank, R.N. et al. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 2004, 14: 55-64.
90. Rajesh, M., Mukhopadhyay, P., Batkai, S. et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 2006, 350: 352-7.
91. Ha, H.C., Hester, L.D. and Snyder, S.H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 2002, 99: 3270-5.
92. Simbulan-Rosenthal, C.M., Ly, D.H., Rosenthal, D.S. et al. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 2000, 97: 11274-9.
93. Zingarelli, B., Hake, P.W., O'Connor, M. et al. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: Role of poly(ADP-ribose) polymerase-1. Am J Physiol Heart Circ Physiol 2004, 286: H1408-15.
94. Szabo, C., Pacher, P. and Swanson, R.A. Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol Sci 2006, 27: 626-30.
95. Virag, L. and Szabo, C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J 2001, 15: 99-107.
96. Geraets, L., Moonen, H.J., Wouters, E.F., Bast, A. and Hageman, G.J. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem Pharmacol 2006, 72: 902-10.
97. Moonen, H.J., Geraets, L., Vaarhorst, A., Bast, A., Wouters, E.F. and Hageman, G.J. Theophylline prevents NAD+ depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem Biophys Res Commun 2005, 338: 1805-10.
98. Alano, C.C., Kauppinen, T.M., Vails, A.V. and Swanson, R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomo-lar concentrations. Proc Natl Acad Sci USA 2006, 103: 9685-90.
99. Bentle, M.S., Reinicke, K.E., Bey, E.A., Spitz, D.R. and Boothman, D.A. Calcium-dependent modulation of poly(ADP-Ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006, 281: 33684-96.